Introducing The New Purdue Pharma
This article was originally published in Scrip
Executive Summary
Mark Timney has been president and CEO of US specialty company Purdue Pharma for just over two years but he's playing a long game to pull the business away from its single-track R&D model towards other opportunities outside pain therapy – its mainstay development area